利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.055 秒)

    Supplemented and unsupplemented tissue sealants, methods of their production and use
    6.
    再颁专利
    Supplemented and unsupplemented tissue sealants, methods of their production and use 有权
    补充和未补充的组织密封剂，其生产和使用的方法

    公开(公告)号：USRE39192E1

    公开(公告)日：2006-07-18

    申请号：US10465854

    申请日：2003-06-20

    申请人： Martin James MacPhee ,  William Nash Drohan ,  Gene Liau ,  Hernan Nunez ,  Wilson H. Burgess ,  Thomas Maciag

    发明人： Martin James MacPhee ,  William Nash Drohan ,  Gene Liau ,  Hernan Nunez ,  Wilson H. Burgess ,  Thomas Maciag

    IPC分类号： A61K38/48 ,  A61K9/70 ,  A61L15/16

    摘要： This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, cytokines, drugs, growth factors, interferons, hormones, lipids, deminearlized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.

    摘要翻译： 本发明提供补充的组织密封剂，其生产方法及其用途。 公开了补充有至少一种细胞毒素或细胞增殖抑制组合物的组织密封剂。 该组合物可以进一步补充有例如一种或多种抗体，止痛剂，抗凝剂，抗炎化合物，抗微生物组合物，细胞因子，药物，生长因子，干扰素，激素，脂质，去神经骨或骨形态发生蛋白，软骨诱导 因子，寡核苷酸聚合物，多糖，多肽，蛋白酶抑制剂，血管收缩剂或血管扩张剂，维生素，矿物质，稳定剂等。

    Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
    8.
    发明授权
    Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1 失效
    与凝血酶降解抗性成纤维细胞生长因子-1有关的组合物，方法和试剂盒

    公开(公告)号：US06982170B1

    公开(公告)日：2006-01-03

    申请号：US10022554

    申请日：2001-12-17

    申请人： Thomas Maciag ,  David S. Ettenson ,  Wilson H. Burgess ,  William N. Drohan

    发明人： Thomas Maciag ,  David S. Ettenson ,  Wilson H. Burgess ,  William N. Drohan

    IPC分类号： C12N15/85

    CPC分类号： C07K14/501

    摘要： The invention relates to novel degradation resistant FGF-1, and methods for producing and using the same. More specifically, the invention relates to identification of a thrombin degradation resistant FGF-1, an a nucleic acid encoding the same. The thrombin degradation resistant FGF-1 can elicit responses that are otherwise typically impeded by degradation of FGF-1 by thrombin. Thrombin degradation resistant FGF-1 is an important molecule for effecting an FGF-1 response that would be otherwise inhibited by thrombin. Thus, the present invention provides a powerful therapeutic for diseases or disorders wherein an FGF-1 response can mediate a reduction in the frequency or intensity of a symptom of the disease or disorder but for degradation of FGF-1 before it can effect the response.

    摘要翻译： 本发明涉及新型降解抗性FGF-1及其生产和使用方法。 更具体地，本发明涉及抗凝血酶降解性FGF-1的鉴定，其是编码该凝血酶的核酸。 凝血酶降解抗性FGF-1可引发其他通常受凝血酶降解FGF-1阻碍的反应。 凝血酶降解抗性FGF-1是影响凝血酶另外抑制的FGF-1应答的重要分子。 因此，本发明为疾病或病症提供强有力的治疗剂，其中FGF-1应答可以介导疾病或病症症状的频率或强度的降低，但是在其能够影响反应之前，可降解FGF-1。

    Recombinant human endothelial cell growth factor
    9.
    再颁专利
    Recombinant human endothelial cell growth factor 有权
    重组人内皮细胞生长因子

    公开(公告)号：USRE37850E1

    公开(公告)日：2002-09-17

    申请号：US09538857

    申请日：2000-03-28

    申请人： Michael C. Jaye ,  Wilson Burgess ,  Thomas Maciag ,  William N. Drohan

    发明人： Michael C. Jaye ,  Wilson Burgess ,  Thomas Maciag ,  William N. Drohan

    IPC分类号： A61K3827

    CPC分类号： C07K14/501 ,  A61K38/00 ,  Y10S930/12

    摘要： Endothelial cell growth factor is achieved through the application of recombinant DNA technology to prepare cloning vehicles encoding the ECGF protein and procedures are disclosed for recovering ECGF protein essentially free of other proteins of human origin. The product is useful for, among other purposes, diagnostic applications and as potential in the treatment of damaged blood vessels or other endothelial cell-lined structures.

    摘要翻译： 内皮细胞生长因子通过应用重组DNA技术来制备编码ECGF蛋白质的克隆载体，公开了用于回收基本上不含人源蛋白质的ECGF蛋白质的方法。 该产品除了其它目的之外还可用于诊断应用，并且用于治疗损伤的血管或其它内皮细胞内衬结构的潜力。